Abilify



Saraswathi, Bharathi, Shesha Garuda, Shankara and Ganesha 17 And wrote this holy Sarasa Bharathi Vilasa through their grace We further like to make it Clear that, while upholding 18 The supremacy of Sripathi In this book, we do not mean Any dis-respect to other gods. Is it possible for anyone To establish the supremacy 19 Of Srihari unless the lapses Of other celestials are established ? As ordained by our Adiguru Acharya Madhwa in his book 20 `Yathi Pranava' Kalpa We Vadiraja Yathi ; have Presented Shankara as inferior to Srihari The lapses on the part of the 21 Celestials are presented Which are revealed in Sruthi and Smruthi to prove The supremacy of Srihari 22 Which the celestials are fully aware of We Vadirja Yathi ; belong to That class of philosophers Suguna Digest July- Sept. 2004. INDEX of DRUGS A ABILIFY . 19 ACCOLATE . 42 ACCUNEB. 43 ACCUZYME spray . 31 ACEON . 26 acetazolamide . 25 acetic acid. 41 acetic acid aluminum acetate. 41 acetic acid hydrocortisone . 41 acetylcysteine. 44 ACTIMMUNE . 38 ACTONEL . 35 ACTOS. 23 ACULAR . 40 acyclovir . 20 acyclovir inj. 20 ADAGEN . 31 ADDERALL XR. 27 adenosine . 24 ADRIAMYCIN RDF . 17 ADVAIR . 42, 43 ADVICOR . 26 AGENERASE . 21 AGGRENOX . 24 ALBENZA . 18 ALBUTEROL HFA . 43 albuterol inhaler. 43 albuterol soln . 43 albuterol syrup, tabs . 43 alclometasone crm, oint 0.05% . 29, 33 ALCOHOL SWABS. 23 ALDACTAZIDE 50 mg 50 mg . 25 ALDARA . 39 ALDURAZYME . 31 ALIMTA. 17 ALINIA . 18 ALKERAN . 17 ALLEGRA-D . 42 allopurinol. 15 allopurinol inj . 15 ALOCRIL . 40 ALOMIDE . 40 ALORA. 36 ALPHAGAN P . 41 ALREX . 40 ALTACE . 26 ALTOPREV. 26 amantadine. 19, 21 AMBIEN . 44 AMICAR 1000 mg. 23 amiloride . 25 amiloride hydrochlorothiazide . 25 aminocaproic acid . 24 aminophylline . 43 aminophylline inj . 43 amiodarone. 24 amiodarone inj . 24 amitriptyline. 14 ammonium lactate 12% . 30 AMOXAPINE . 14 amoxicillin . 11 amoxicillin clavulanate. 11 AMOXIL PEDIATRIC DROPS . 11 ampicillin . 11 45.

Abilify 20mg side effects

On October 20, 2006, the FDA approved AstraZeneca's application for the use of Seroquel quietiapine ; in the treatment of major depressive episodes associated with bipolar disorder8--despite the fact that a major government review of off-label prescribing of antipsychotics found no evidence demonstrating clinical efficacy for bipolar depression.9 Strangely, at the time that the FDA was issuing approvals for use of antipsychotic drugs in children, officials deferred the pediatric study requirements for Abiliry until December 2011. Were these approvals science-based decisions or marketing decisions? These actions were taken at the time that Congress began to examine the reauthorization of PDUFA Prescription Drug User Fee Act, 1992 ; and the cash incentives under FDAMA FDA Modernization Act, 1997 ; granting companies a six-month patent extension for testing their drugs in children. All of these administrative approvals were issued without presentation of data to support a clinical justification in spite of the fact that psychiatric diagnoses for which these drugs were approved for adults--i.e., schizophrenia and bipolar disorder--are highly controversial when applied to children. Yet, industryfinanced consensus panels diluted the bipolar diagnostic criteria for children to include behaviors associated with ADHD.10 Indeed, a Vanderbilt University study found that 53% of children prescribed antipsychotics are diagnosed with ADHD.11 With these pediatric approvals, the FDA has sewn the seeds for a catastrophic assault on the health of American children who do not have the debilitating conditions for which they were approved for adults--namely, psychosis--the most toxic drugs carrying a high risk of serious lifethreatening adverse events. Dr. von Eschenbach, I doubt that you would sanction the prescribing or testing ; of cancer fighting drugs in children who do not have cancer. Antipsychotics are the equivalent of chemotherapy. Yet, despite these drugs' undisputable debilitating effects, the FDA is endorsing the testing of marketing of antipsychotics for children who are not psychotic. If allowed to stand, these secretly arrived at decisions will greatly undermine the physical and mental health of thousands of children, not to mention the public's confidence in the.
MAOI Nardil phenylzine ; Parnate trancylpromine ; Antihyperkinesis - ADD ADHD; Narcolepsy: CNS Agents Adderall XR dextroamphet., IR ER, 50: ; Adderall dextroamphetamine salts ; Amphetamine salt combo generic for Adderall ; Concerta methylphenidate IR ER 22: 78% ; Dextroamphetamine generic for Dexedrine ; Desoxyn methamphetamine ; Dextroamphetamine SA generic for Dexedrine SA ; Dexedrine dextroamphetamine ; Dextrostat generic for Dexedrine ; Dexedrine Elixir dexedrine elixir ; Focalin dexmethylphenidate ; Dexedrine SA dexedrine sustained release ; Focalin XR dexmethlyphenidate, IR ER, 50: ; Pemoline Cylert ; Metadate CD methylphenidate, IR ER, 30: 70% ; Provigil modafinil ; Metadate ER methlyphenidate ER ; Ritalin methylphenidate ; Methamphetamine generic for Desoxyn ; Ritalin SR methylphenidate sustained release ; Methylin generic for Ritalin ; Strattera atomoxetine ; Methylin ER generic for Ritalin SR ; Methylphenidate generic for Ritalin ; Methylphenidate SR generic for Ritalin SR ; Ritalin LA methylphenidate, IR ER, 50: ; Antipsychotics - Atypical & Combinations Clozapine generic for Clozaril ; Qbilify aripiprazole ; Risperdal risperdone ; Qbilify Oral Solution aripiprazole oral solution ; Seroquel quetiapine ; Clozaril clozapine ; Fazalco clozapine ODT ; Geodon ziprasidone ; Geodon IM ziprasidone Injectable ; Risperdal Consta risperidone microspheres ; Risperdal Tab Rapdis risperdone rapid dissolve tab ; Symbyax olanzapine fluoxetine ; Zyprexa olanzapine ; Zyprexa IM olanzapine injectable ; Zyprexa Zydis olanzapine rapid dissolve tab ; 1.
If the applicant is taking one of these drugs for the reason stated, he she is not eligible for coverage. This list is a reference guide for prequalifying cases; it is not intended to be an exhaustive, all-inclusive list. Drug name Actimmune Qbilify Akineton Aldazine Amantadine Antabuse Aranesp Aricept Artane Avonex AZT Bendopa Benztropine mesylate Betaseron Bromocriptine Carbidopa Chlorpormazine Cladribine Clorazil Clozapine Codeine Cogentin Cognex Combivir Comtan Copaxone Dantrium Dantrolene Darvocet Demerol Deprynel Dilaudid Donepezil Dopar Duragesic Edrophonium Chloride Eldepryl Epogen Eulexin Exelan Fluphenazine Flutamide Glatiramer acetate Haldol Hydergine Infergen Insulin Interferon Intron-A Alternate name for same drug Interferon gamma 1-b Aripiprazole Biperiden Mellaril, Thioridazine Symmetrel Disulfiram Darepeotinalfa Donepezil Novohexidyl Interferon, Rebif Retrovir, Apo-zidovudine Levodopa Cogentin Interferon, Recombinant Parlodel Sinemet Thorazine Leustatin Clozapine Clorazil Apo-benztropine Tacrine HCl Zidovudine, Lamivudine Entacapone Glatiramer acetate Dantrolene Dantrium Condition for which drug is most commonly used Chronic granulomatous disease Schizophrenia Parkinson's disease Mental health Parkinson's disease Alcoholism chronic anemia; renal failure Dementia Parkinson's disease Multiple sclerosis HIV Parkinson's disease Parkinson's disease Multiple sclerosis Parkinson's disease Parkinson's disease Mental health Leukemia, multiple sclerosis Mental health Mental health Pain control Parkinson's disease Dementia HIV Parkinson's disease Multiple sclerosis Multiple sclerosis Cerebral palsy, multiple sclerosis Pain control Pain control Dementia, Parkinson's disease Pain control Dementia Parkinson's disease Pain control Myasthenia gravis Parkinson's disease Renal failure, anemia of chronic disease If for recurrent prostate cancer Dementia Mental health Cancer Multiple sclerosis Mental health Dementia Hepatitis, other liver disease Diabetes Multiple sclerosis Cancer.
Abilify medicine bipolar
P A COMMENTS Preparation of Synagis: Follow directions on package insert carefully for mixing. C DO NOT SHAKE VIAL. C DO NOT FLUSH THE DILUENT DIRECTLY ONTO THE POWDER. Synagis foams excessively when shaken and the foam may not settle until after the reconstituted drug's shelf life of 6 hours has lapsed. C Let the diluent slowly run down the side of the vial to the powder. C Gently swirl the contents or roll the vial to mix the diluent and powder Payment Methodologies: Drug Reimbursement Reimbursement is * direct manufacturer purchase price plus 10 percent direct price + 10% ; . Administration Cost The provider may bill for services as directed in the Physician Services Provider Manual, SECTION 2, Chapter 2, COVERED SERVICES, item 23, which describes services associated with the use of an injection code and anafranil. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. 37hours. In the ER of GH #1, she was noted to have a generally distended abdomen with bowel sounds present. Initial treatment included Morphine for pain, intravenous fluids for rehydration, and being given nothing by mouth. Her regular oral medications were held and she was not administered replacement intravenous corticosteroids. Laboratory investigations were reported as follows: 1. 2. 3. White blood cell count 21.0, Platelets 442, Sodium 125, and Creatinine 102 and luvox.

Abilify otsuka bristol

Aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased. Carbamazepine: Coadministration of carbamazepine 200 mg BID ; , a potent CYP3A4 inducer, with aripiprazole 30 mg QD ; resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole see CLINICAL PHARMACOLOGY: DrugDrug Interactions ; . Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10- to 30-mg day doses of aripiprazole had no significant effect on metabolism by CYP2D6 dextromethorphan ; , CYP2C9 warfarin ; , CYP2C19 omeprazole, warfarin ; , and CYP3A4 dextromethorphan ; substrates. Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro see CLINICAL PHARMACOLOGY: Drug-Drug Interactions ; . Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY. Meat wrapper. She left there because she had a breakdown. She worked at the House of Prime, a meat market, in 1995 or 1996 for a month, earning a total of about 0. She worked behind the meat counter and sold meat to customers. The meat was already cut. She had no butcher experience. She left there because she had emotional problems. She worked at Kroger in 1996 in the meat department. She earned 3.00. She could not handle the job emotionally. Plaintiff had no prior worker's compensation case. She was asked about Howard Distributing Co., Grant & Silverman, and V.C. Inc on Six Mile and had no recollection of them. She worked at the Produce Palace in 1996, earning 3. She left because she had emotional problems. She worked at the J Shop, Inc. in Pontiac, where she assembled little parts in 1998 and 1999. She earned , 095. She left there because she moved to live with her parents. She was asked about Outsource America International, Melco, Inc., Sibra, Big Boy in Hartland, Travis Hamburgers and Applebee's. She could not recall any of them. She worked at the Stir Crazy Caf in 1999 as a hostess, but could not handle the job. She worked at Meijer for a short period in 1999 in the deli. She could not handle it emotionally. She worked at Yanni's Coney Island, a restaurant. She worked at Burlington Coat Factory for one week in 2000. She worked at Ram's Horn Rochester in 2000, then in Rochester Hills, for a year. That is a Hartland Family Restaurant, the same corporation as Ram's Horn. She worked at Mill St. Bar for three months. She waited tables there in 2000. She worked at IHOP a long time ago, not in 2000. She worked at Cracker Barrel for a short period of time in 2001. She earned 8. It was too much for her. Plaintiff testified that she takes Wellbutrin SR, Tegretol, and Lortab for pain as needed. She had been on Lortab through Dr. Montgomery and Dr. Sheila Simpson. She also takes Abllify for mood swings, once a month. Dr. Bagga is her doctor. She has taken Wellbutrin SR for three years for depression. Tegretol is a mood stabilizer she has taken for three years. She did not recall taking Acolate. She takes Klonopin for sleep, Seroquel for mood stability, and Levothyroid. She also has B12 shots. Plaintiff acknowledged that, in the early 1970s she experimented with drugs. She was admitted to a facility for treatment of drugs. She did not recall having a relapse of drug use in 2001. In June 2003, she had her gall bladder removed. She has acute anxiety and takes Xanax at times. She did not recall injuring her ankle before. She smokes 1-1 packs of cigarettes a day. Plaintiff testified she is a borderline diabetic. She was 5'5" tall and weighed 228 pounds at the time of hearing. At one point she weighed 250 pounds. She suffered from fatigue in 2002. She did not remember passing out at her sister's house in December 2002. On February 11, 2003, she had headaches all the time. In March 2003, she had cramping in her legs. She did not recall telling Dr. Sanghvi in August 2003 that she was and keppra.
About killing herself. The deputy contacted the medical unit and asked that Prisoner No. 4 be housed in a medical cell, but this request was refused. A short time later, Prisoner No. 4 was found curled in a fetal position on the floor next to the deputies' desk. In the early morning hours of April 2, Prisoner No. 4 again said she was going to kill herself. She was eventually placed in a special detention cell in handcuffs and leg irons. A deputy threatened to shock her with a taser. When she began screaming and banging her head against the window of the cell, a helmet was placed on her head and secured with tape. The "Special Detention Documentation" form indicates that mental health staff was not notified. 43. On several other occasions April 11, 12, 20, and 25, 2003; May 11.

Seizure Seizures occurred in 0.1% 926 ; of oral aripiprazole-treated patients with schizophrenia in short-term, placebo-controlled trials. In short-term, placebo-controlled clinical trials of patients with bipolar mania, 0.3% 2 597 ; of oral aripiprazole-treated patients and 0.2% 1 436 ; of placebo-treated patients experienced seizures. In short-term, placebocontrolled clinical trials of patients with agitation associated with schizophrenia or bipolar mania, 0.2% 1 501 ; of aripiprazole injection-treated patients and 0% 0 220 ; of placebo-treated patients experienced seizures. As with other antipsychotic drugs, aripiprazole should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, eg, Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Potential for Cognitive and Motor Impairment In short-term, placebo-controlled trials of schizophrenia, somnolence was reported in 11% of patients on oral ABILIFY compared to 8% of patients on placebo; somnolence led to discontinuation in 0.1% 926 ; of patients with schizophrenia on oral ABILIFY in short-term, placebo-controlled trials. In short-term, placebo-controlled trials of bipolar mania, somnolence was reported in 14% of patients on oral ABILIFY compared to 7% of patients on placebo, but did not lead to discontinuation of any patients with bipolar mania. In short-term, placebo-controlled trials of patients with agitation associated with schizophrenia or bipolar mania, somnolence including sedation ; was reported in 9% of patients on ABILIFY Injection compared to 6% of patients on placebo. Somnolence including sedation ; did not lead to discontinuation of any patients with agitation associated with schizophrenia or bipolar mania. Despite the relatively modest increased incidence of somnolence compared to placebo, ABILIFY, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely. Body Temperature Regulation and bupropion. Respiratory Virus Isolation Detection Data During the 2007-2008 influenza season, CISP received weekly reports of laboratory detections and isolations of influenza and other respiratory viruses predominantly RSV ; from 22 participating sites situated throughout California, including hospital, academic, public health, and private laboratories. The CDPH Viral and Rickettsial Disease Laboratory VRDL ; also encouraged submission of clinical respiratory specimens and isolates from a wide variety of settings, including local public health and clinical laboratory partners, hospitalized cases of severe respiratory illness, outpatient clinics and outbreak settings. Selected isolates were forwarded to CDC for confirmation and further analysis In the 2007-08 season, a total of 1008 clinical specimens were tested at VRDL using Rmix shell vial testing and viral isolation in primary monkey kidney and human fetal diploid cells; 505 50% ; had positive yield by isolation. 409 isolates were positive for influenza: a majority 288 409; 70% ; were identified as influenza A compared to influenza B 121 409; 30% ; . These results are comparable to those reported by the World Health Organization National Respiratory and Enteric Virus Surveillance System NREVSS ; laboratory network, where across the US, of the 39, 453 influenza viruses isolated, 28, 105 71.2% ; were influenza A viruses and 11, 348 28.8% ; were influenza B viruses. Ninety-six of the 505 isolates had non-influenza viral pathogens diagnosed, including rhinovirus 34 parainfluenza 26 adenovirus 20 ; , RSV 4 ; , coxsackievirus 4 echovirus 4 herpes 3 human metapneumovirus 1. Abilify injection continues to be indicated for the treatment of adults with agitation associated with schizophrenia or bipolar i disorder, manic or mixed and remeron. Ask your doctor or healthcare professional if ABILIFY is right for you. Visit abilify bipolardisorder to find out more. ABILIFY tablets are available in 2-mg, 5-mg, 10-mg, and 30-mg strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose and elavil. Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10- to 30-mg day doses of aripiprazole had no significant effect on metabolism by CYP2D6 dextromethorphan ; , CYP2C9 warfarin ; , CYP2C19 omeprazole, warfarin ; , and CYP3A4 dextromethorphan ; substrates. Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro see PRECAUTIONS: Drug-Drug Interactions ; . Aripiprazole had no clinically important interactions with the following drugs: Famotidine: Coadministration of aripiprazole given in a single dose of 15 mg ; with a 40-mg single dose of the H2 antagonist famotidine, a potent gastric acid blocker, decreased the solubility of aripiprazole and, hence, its rate of absorption, reducing by 37% and 21% the Cmax of aripiprazole and dehydro-aripiprazole, respectively, and by 13% and 15%, respectively, the extent of absorption AUC ; . No dosage adjustment of aripiprazole is required when administered concomitantly with famotidine. Valproate: When valproate 500-1500 mg day ; and aripiprazole 30 mg day ; were coadministered at steady state, the Cmax and AUC of aripiprazole were decreased by 25%. No dosage adjustment of aripiprazole is required when administered concomitantly with valproate. Lithium: A pharmacokinetic interaction of aripiprazole with lithium is unlikely because lithium is not bound to plasma proteins, is not metabolized, and is almost entirely excreted unchanged in urine. Coadministration of therapeutic doses of lithium 12001800 mg day ; for 21 days with aripiprazole 30 mg day ; did not result in clinically significant changes in the pharmacokinetics of aripiprazole or its active metabolite, dehydro-aripiprazole Cmax and AUC increased by less than 20% ; . No dosage adjustment of aripiprazole is required when administered concomitantly with lithium. Dextromethorphan: Aripiprazole at doses of 10 to mg per day for 14 days had no effect on dextromethorphan's O-dealkylation to its major metabolite, dextrorphan, a pathway known to be dependent on CYP2D6 activity. Aripiprazole also had no effect on dextromethorphan's N-demethylation to its metabolite 3-methyoxymorphan, a pathway. In both positive and negative ioa modes. The positive ion mass spectrum of the aqueous extract Figure 6.2A ; cIearIy showed two probable protonated molecular ions and endep. MIDAZOLAM HCL SYRP PROSOM TABS RESTORIL CAPS LUNESTA AMBIEN SONATA CAPS RISPERDAL M TAB RISPERDAL CONSA 1. Geodon has dose consolidation edit of 2 per day. 2. Abilify 1 day. 3. Zyprexa: maximal recommended dose showing efficacy is 20mg. 4. Seroquel 25mg is available without PA if the following conditions are met: a. 65 years old or older, and doseage is for 3 or more per day, and Seroquel 25mg is in the profile within the last 45 days. Use PA Form # 20420 Use PA Form # 20420 Use PA Form # 20420 Elderly over 65 ; exempt, but previous quantity limits still apply. Use PA Form # 30110.
Gross margin percentages were 63.7%, 63.9% and 69.4% in 2003, 2002 and 2001, respectively. Gross margins were negatively impacted in 2003 due to increased sales of lower-margin products in the OTN segment, million in accelerated depreciation charges and a million charge for asset impairment and other restructuring expenses largely offset by increased sales of higher margin products such as PRAVACHOL. The lower gross margin in 2002 compared to 2001 was principally due to the impact of generic competition in the United States for GLUCOPHAGE * IR, TAXOL and BUSPAR, and an adverse change in product mix due to increased sales in the OTN segment. The effective income tax rate on earnings from continuing operations before minority interest and income taxes was 25.9% in 2003 compared with 14.2% in 2002 and 9.4% in 2001. The increase in the 2003 effective tax rate over the 2002 effective tax rate is primarily due to the decrease in effective tax rate benefit from operations in Ireland, Puerto Rico and Switzerland, treatment of provisions for certain litigation reserves as non-deductible, and an increase in estimates for contingent tax matters in 2003 compared to 2002. The increase in the 2002 effective tax rate over the 2001 effective tax rate was primarily due to the decrease in effective tax rate benefit from operations in Ireland, Puerto Rico and Switzerland, and the provision of 5 million of valuation allowances, comprised of 2 million related to certain state and foreign net deferred tax assets, million related to certain state and foreign tax net operating loss and tax credit carryforwards, partially offset by a 1 million net release of tax contingency reserves related primarily to the settlement of prior year tax matters, and the determination by the Company as to the expected settlement of ongoing tax litigation, which was resolved in 2003. The Company currently believes that the state net deferred tax assets, state net operating loss and tax credit carryforwards, and foreign net operating loss and tax credit carryforwards for which valuation allowances have been provided, more likely than not, will not be realized in the future. The lower effective income tax rate in 2001 results primarily from lower pre-tax income in the United States, due to the write-off of acquired in-process research and development, as well as proportionately greater tax benefits from income earned in lower tax rate jurisdictions such as Ireland, Puerto Rico and Switzerland. Expenses Total costs and expenses, as a percentage of sales, were 77.5% in 2003 compared with 84.8% in 2002 and 87.5% in 2001. Cost of products sold, as a percentage of sales, increased over the last three years to 36.3% in 2003 compared with 36.1% in 2002 and 30.6% in 2001, principally due to increased sales of lower-margin products from OTN largely offset by increased sales of higher margin products such as PRAVACHOL. In 2003, cost of products sold includes million of accelerated depreciation of assets in manufacturing facilities in North America expected to be closed by the end of 2006 and a million charge for asset impairment and other restructuring expenses. Cost of products sold in 2002 included a million reversal of prior period reserves for inventory write-offs related to cancelled actions and in 2001 included million of other restructuring expenses. Marketing, selling and administrative expenses, as a percentage of sales, decreased to 22.3% in 2003 from 22.8% in 2002. In 2003, marketing, selling and administrative expenses increased 13% to , 660 million from , 124 million in 2002 primarily due to increased sales support for ABILIFY * and AVAPRO * AVALIDE * , higher pension costs, higher charges related to system infrastructure, higher insurance premiums, and unfavorable foreign exchange impact, principally related to the euro. Marketing and citalopram. Like all medicines, ABILIFY can cause side effects although not everybody gets them. Common side effects greater than 1 in 100, less than 1 in 10 patients ; Headache, unusual tiredness or weakness, nausea, vomiting, an uncomfortable feeling in the stomach, constipation, light-headedness, trouble sleeping, restlessness, sleepiness, shaking and blurred vision. If the condition continues or gets worse, contact your doctor as soon as possible. Uncommon side effects greater than 1 in 1, 000, less than 1 in 100 patients ; Uncontrollable twitching or jerking movements and seizure. Some people may feel dizzy, especially when getting up from a lying or sitting position, or may experience a fast heart rate. If this happens, contact your doctor as soon as possible. Rare side effects greater than 1 in 10, 000, less than 1 in 1, 000 patients ; Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate. If this happens while you are taking ABILIFY, contact your doctor immediately. Very rare side effects less than 1 in 10, 000 patients ; Changes in the levels of some blood cells; unusual heart beat, sudden unexplained death, heart attack; allergic reaction e.g. swelling in the mouth, tongue, face and throat, itching, rash high blood sugar, onset or worsening of diabetes, ketoacidosis ketones in the blood and urine ; or coma, low sodium level in the blood; weight gain, weight loss, anorexia; nervousness, agitation; thoughts of suicide; speech disorder, fainting; high blood pressure; spasm of the muscles around the voice box, accidental inhalation of food with risk of pneumonia, difficulty in swallowing; inflammation of the pancreas, increased production of saliva; inflammation of the liver, yellowing of the skin and white part of eyes, reports of abnormal liver test values; skin rash and sensitivity to light, unusual hair loss or thinning, stiffness or cramps, muscle pain, weakness; involuntary loss of urine, difficulty in passing urine; prolonged and or painful erection; and difficulty controlling core body temperature or overheating. In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In addition, cases of stroke or "mini" stroke have been reported. If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. The Formal Project Prize was established by the College Council. This Prize is awarded to the best paper presented at the Formal Project Prize Session, usually held as part of the College Annual Scientific Meeting ASM ; * or any other meeting approved by the Council. Registered Trainees in Anesthesia, Intensive Care or Pain Medicine and Fellows within one year of award of the corresponding Diploma of Fellowship are invited to submit the abstract of their formal projects to the organizing committee of the ASM for consideration of the award. Projects that have previously been published as a full manuscript or have been presented in another local or overseas meeting will also be considered. However, projects that have previously entered in another Formal Project Prize competition will be excluded. The Chairman of the Board of Education will appoint at least two judges to select a number of projects for presentation during the "Formal Project Prize Session" at the ASM. The criteria for selection will be based on the scientific content of the submitted abstracts. The final assessment for the award will also include the quality of performance during the presentation and discussion afterwards. The College reserves the right not to award the Prize if none of the project achieves a sufficiently high standard and haldol and Buy abilify online.
Stigma impacts on treatment at every point. a Many heroin users themselves share community attitudes, and keep striving for the acceptable outcome of abstinence rather than entering methadone treatment a Practitioners involved in delivering treatment may express their negativity to drug users through punitive and exploitative approaches to treatment a Communities and administrators feel more comfortable with highly regulated treatment, expressing punitive attitudes through restrictive and inflexible program rules a Political and community support for methadone treatment is inconsistent. The stigma associated with addiction is a powerful indication that those in the community who are anxious to send the right message about drugs have in fact been devastatingly successful: a Heroin is feared. a Those who use it are disliked. a Those who treat heroin addiction tend to find themselves professionally marginalised. Stigma probably deters many people from experimenting with opioids, and may therefore be seen as having a public health role although this is difficult to assess ; . The downside of stigma is that those who do succumb to heroin addiction find their plight intensified, and rehabilitation more difficult, as a result of being stigmatised and marginalised. The Food and Drug Administration has determined that the treatment of behavioral disorders in elderly patients with dementia with atypical second generation ; antipsychotic medications is associated with increased mortality. Of a total of seventeen placebo controlled trials performed with olanzapine Zyprexa ; , aripiprazole Abilify ; , risperidone Risperdal ; , or quetiapine Seroquel ; in elderly demented patients with behavioral disorders, fifteen showed numerical increases in mortality in the drug-treated group compared to the placebo-treated patients. These studies enrolled a total of 5106 patients, and several analyses have demonstrated an approximately 1.6-1.7 fold increase in mortality in these studies. Examination of the specific causes of these deaths revealed that most were either due to heart related events e.g., heart failure, sudden death ; or infections mostly pneumonia and fluoxetine. ADULT CARE I.1. I.2. Trauma and Hypovolemic Supportive Care. Cervical spine immobilization. a ; b ; c ; I.3. I.4. I.5. Secure patient to LBB in a manner that will allow it to be safely turned to the side if patient vomits. Check patients back before logrolling onto LBB. Assess neurologic function before and after moving to LBB.

Abilify breastfeeding hale

Procedures for the Prescriber - Even though the pharmacy benefit is administered by Presbyterian Health Plan, the prescriber DOES NOT need to be a participating provider with Presbyterian Health Plan to prescribe drug items: The prescriber will have access to the PDL on the internet on the page for the NMRX Pharmacy PDL Plan at : phs or selecting NMRX at : phs facilities pharmacy formulary.shtml.

What ABILIFY contains The active substance is aripiprazole. Each ml contains 7.5 mg aripiprazole. A vial contains 9.75 mg 1.3 ml ; aripiprazole. The other ingredients are sulfobutylether -cyclodextrin SBECD ; , tartaric acid, sodium hydroxide, and water for injection. What ABILIFY looks like and contents of the pack The ABILIFY solution for injection is a clear, colourless, aqueous solution. Each carton contains one single-use type I glass vial with a rubber butyl stopper and a "flip-off" aluminium seal. Marketing Authorisation Holder Otsuka Pharmaceutical Europe Ltd. Hunton House Highbridge Business Park, Oxford Road Uxbridge - Middlesex UB8 1HU - United Kingdom Manufacturer Bristol-Myers Squibb S.r.l. Contrada Fontana del Ceraso I-03012 Anagni-Frosinone - Italy For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgique Belgi Belgien BRISTOL-MYERS SQUIBB BELGIUM S.A. N.V. Tl Tel: + 32 2 352 BRISTOL-MYERS SQUIBB GYGYSZERKERESKEDELMI KFT. Te.: + 359 800 12 Cesk republika BRISTOL-MYERS SQUIBB SPOL. S R.O. Tel: + 420 221 016 Danmark BRISTOL-MYERS SQUIBB Tlf: + 45 Luxembourg Luxemburg BRISTOL-MYERS SQUIBB BELGIUM S.A. N.V. Tl Tel: + 32 2 352 Magyarorszg BRISTOL-MYERS SQUIBB GYGYSZERKERESKEDELMI KFT. Tel.: + 36 1 301 Malta BRISTOL-MYERS SQUIBB S.R.L. Tel: + 39 06 Nederland BRISTOL-MYERS SQUIBB BV Tel: + 31 34 857.
Chelating agents in the drug dosage design of iron preparations. Huang, Hua-pin. Comparative pharmacokinetic studies of dyphylline and some dyphylline prodrugs.
ENDEAVOR IV to 270 days Description of Event Endeavor N 773 patients ; 38 740 ; Target Vessel Failure Stent Thrombosis sub-acute 30 days ; Stent Thrombosis late 30 days ; Cerebrovascular Accident CVA ; 5.8% 43 740 ; Control N 775 patients ; 32 734 ; 4.8% 35 734 ; Endeavor III to 720 days Endeavor N 323 patients ; 43 313 ; 13.7% 43 313 ; Control N 113 patients ; 11 112 ; 10.7% 12 112 ; 10.4% 60 577 ; Endeavor II to 1080 days Endeavor N 598 patients ; Control N 599 patients ; 101 579 ; 19.2% 111 579 ; 0.9% 5 579 ; 0.0% 0 579 ; 1.2% 7 579 ; 5.2% 5 97 ; 1.0% 1 97 ; 0.0% 0 97 ; 1.0% 1 97 ; Endeavor I to 1440 days Endeavor N 100 patients and buy anafranil.
Key The * symbol next to a drug signifies subject to non-formulary status when generic is available throughout the year. The symbol [CARE] next to a drug name indicates that the drug has been noted as having an increased risk in elderly individuals. Caution should be exhibited when prescribing these agents to the elderly. The symbol [G] next to a drug name indicates that a generic is available for at least one or more strengths of the brand medication. The symbol [INJ] next to a drug name indicates that the drug is available in injectable form only. The symbol [PAR] next to a drug name indicates that prior authorization may apply. The symbol [QLL] next to a drug name indicates that quantities dispensed may be limited. The symbol [ST] next to a drug name indicates that Step Therapy may apply. 2006 Medicare High Performance Abridged Publication File A a b otic ABILIFY acetaminophen w codeine acetic acid acticin ACTIQ acyclovir ADDERALL XR * [CARE] adenosine [INJ] ADVAIR DISKUS albuterol inh, tab, syrup HFA inhaler nonformulary ; ALCOHOL SWABS [OTC] ALDARA allopurinol ALOXI [INJ] ALPHAGAN P Tier Restrictions Limits 1 2 1. The recommended starting and target dose for ABILIFY is 10 mg day or 15 mg day administered on a once-aday schedule without regard to meals. ABILIFY has been systematically evaluated and shown to be effective in a dose range of 10 mg day to 30 mg day, when administered as the tablet formulation; however, doses higher than 10 mg day or 15 mg day were not more effective than 10 mg day or 15 mg day. Dosage increases should not be made before 2 weeks, the time needed to achieve steady state [see CLINICAL STUDIES 14.1 ; ]. In the two positive, 3-week, placebo-controlled trials n 268; n 248 ; which evaluated ABILIFY 15 or 30 mg day, once daily with a starting dose of 30 mg day ; , ABILIFY was superior to placebo in the reduction of Y-MRS total score and CGI-BP Severity of Illness score mania ; . A trial was conducted in patients meeting DSM-IV criteria for Bipolar I Disorder with a recent manic or mixed episode who had been stabilized on open-label ABILIFY and who had maintained a clinical response for at least 6 weeks. The first phase of this trial was an open-label stabilization period in which inpatients and outpatients were clinically stabilized and then maintained on open-label ABILIFY 15 or 30 mg day, with a starting dose of 30 mg day ; for at least 6 consecutive weeks. One hundred sixty-one outpatients were then randomized in a double-blind fashion, to either the same dose of ABILIFY they were on at the end of the stabilization and maintenance period or placebo and were then monitored for manic or depressive relapse. During the randomization phase, ABILIFY was superior to placebo on time to the number of combined affective relapses manic plus depressive ; , the primary outcome measure for this study. The majority of these relapses were due to manic rather than depressive symptoms. There is insufficient data to know whether ABILIFY is effective in delaying the time to occurrence of depression in patients with Bipolar I Disorder. An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age and gender; however, there were insufficient numbers of patients in each of the ethnic groups to adequately assess intergroup differences. A ABACAVIR SULFATE ction 100 . 308 ABACAVIR SULFATE with LAMIVUDINE and ZIDOVUDINE ction 100 . 308 Abbocillin-V SI ; .Antiinfectives for systemic use. 159 ntal. 287 Abbocillin-VK Filmtab SI ; .Antiinfectives for systemic use. 158, 159 ntal. 287 ABCIXIMAB . 99 Abilify BQ ; . 228 ACAMPROSATE CALCIUM. 242 ACARBOSE. 88 Accomin Adult Tonic WT ; .Repatriation Schedule . 398 Accu-Chek Active RD ; . 264 Accu-Chek Go RD ; . 264 Accupril PF ; . 122 Accure 10 AF ; . 132 Accure 20 AF ; . 132 Accuretic 10 12.5mg PF ; . 123 Accuretic 20 12.5mg PF ; . 123 Accutrend Glucose RD ; . 264 Acenorm 12.5 mg AF ; . 119 Acenorm 25 mg AF ; . 119 Acenorm 50 mg AF ; . 119 ACETAZOLAMIDE. 258 ACETYLCYSTEINE . 254 Achromycin SI ; .Antiinfectives for systemic use. 156 ntal. 285 ACICLOVIR .Antiinfectives for systemic use. 173 nsory organs . 256 Aciclovir-BC BG ; . 173, 174 Acihexal HX ; . 173, 174 Aci-Jel JC ; .Repatriation Schedule . 408 Acimax Tablets AL ; . 74 ACITRETIN. 129 Aclin AF ; ntal. 296 .Musculo-skeletal system . 202 Aclin 200 AF ; ntal. 296 .Musculo-skeletal system . 202 Aclor 125 AW ; .Antiinfectives for systemic use. 162 ntal. 291 Aclor 250 AW ; .Antiinfectives for systemic use. 162 ntal. 291 Actilax AF ; . 80 Actilyse BY ; . 101 Actisorb Plus MAC031 JJ ; .Repatriation Schedule . 425 Actonel AV ; .Musculo-skeletal system . 209 .Repatriation Schedule . 413 Actonel Once-a-Week AV ; .Musculo-skeletal system . 209 .Repatriation Schedule . 413 Actos LY ; . 91, 92 Actrapid NO ; . 85 Actrapid Penfill 3 ml NO ; . 85 Actuss SI ; .Repatriation Schedule . 418 Acyclo-V 200 AF ; . 173 Acyclo-V 800 AF ; . 174 Adalat 10 BN ; . 116 Adalat 20 BN ; . 116 Adalat Oros 20mg BN ; rdiovascular system . 116, 117 .Repatriation Schedule . 400 Adalat Oros 30 BN ; . 116 Adalat Oros 60 BN ; . 116 ADALIMUMAB . 190 Adaptic 2012 JJ ; .Repatriation Schedule . 431 Adefin 10 AF ; . 116 Adefin 20 AF ; . 116 Adefin XL 30 AF ; 116 Adefin XL 60 AF ; 116 ADRENALINE rdiovascular system . 107 ntal. 282, 305 .Doctor's Bag Supplies . 65 .Respiratory system. 252 Adriamycin Solution PH ; . 180, 181 Advantage II RD ; . 264 Advantan CS ; . 131 Aerodiol SE ; . 138 Agenerase GK ; ction 100 . 308 Aggrastat MK ; . 101 Agon SR TP ; . 115, 116 Airomir MM ; .Doctor's Bag Supplies . 66 .Respiratory system. 246 Airomir Autohaler MM ; . 246 Akamin 50 AF ; . 155 Akamin 100 AF ; . 155 Akineton AB ; . 224 Albalon-A AG ; .Repatriation Schedule . 419 Albalon Liquifilm AG ; .Repatriation Schedule . 419 ALBENDAZOLE. 245 Albey Bee Venom TH ; . 263 Albey Paper Wasp Venom TH ; . 263 Albey Yellow Jacket Venom TH ; . 263 Aldactone PH ; . 112 Aldazine 10 AF ; . 227 Aldazine 25 AF ; . 227 Aldazine 50 AF ; . 227 Aldazine 100 AF ; . 227. Risperdal risperdal - the ambush of being bipolar group discussion clinical trial: evaluation of effectiveness of risperdal consta compared to abilify over a two-year period in patients with schizophrenia anyone familiar with risperdal and if it works better than seroquel on hypomania and extreme from the seroquel, but i've heard a lot of mixed reviews in regards to the risperdal.

Abilify side effects medication

[1] Ubell R., Engineers turn to e-learning IEEE Spectrum , Volume: 37 Issue: Oct. 2000. ABBOKINASE INJECTION . 78 ABELCET INTRAVENOUS . 47 ABILIFY DISCMELT ORAL . 66 ABILIFY ORAL. 66 ABRAXANE INTRAVENOUS. 56 ACCOLATE ORAL . 168 ACCUHIST LA ORAL . 168 ACCUHIST ORAL . 169 ACCUPRIL ORAL . 82 ACCURETIC ORAL . 82 ACCUTANE ORAL . 102 ACCUZYME EXTERNAL LIQD . 102 ACCUZYME EXTERNAL OINT . 102 ACCUZYME SE EXTERNAL . 102 acebutolol hcl oral . 82 ACEON ORAL . 82 ACETADOTE INTRAVENOUS . 191 acetaminophen w codeine oral . 16 oral. 16 acetazolamide oral . 82 ACETAZOLAMIDE SODIUM INJECTION . 82 acetic acid otic ; otic . 167 acetic acid vaginal. 47 acetic acid-aluminum acetate otic . 167 ACETOHEXAMIDE ORAL. 74 ACIPHEX ORAL . 118 ACLOVATE EXTERNAL CREA. 126 ACLOVATE EXTERNAL OINT . 126 ACTHAR HP INJECTION . 126 ACTHIB INTRAMUSCULAR . 152 ACTIGALL ORAL . 118 ACTIMMUNE SUBCUTANEOUS. 56 ACTIQ BUCCAL . 16 ACTIVASE INTRAVENOUS. 78 ACTIVELLA ORAL . 126 ACTONEL ORAL TABS 30mg . 127 ACTONEL ORAL TABS 35mg . 127 ACTONEL ORAL TABS 5mg . 127 ACTONEL WITH CALCIUM ORAL . 127 ACTOPLUS MET ORAL . 74 ACTOS ORAL. 74 ACUFLEX ORAL . 16.
The Standard Model SM ; of electroweak and strong interactions is the name given to the current theory of elementary particles and their interactions, excluding gravitational interaction. The Standard Model was developed in the 1960's and 70's [1518]. It incorporated all that was at that time known about elementary particles, and it has predicted accurately the outcome of a great number of experiments performed thereafter. The basic constituents of the SM are six quarks and six leptons and forces acting between them. The quarks are named up u ; , down d ; , charm c ; , strange s ; , top t ; and bottom b ; , and the leptons consist of the electron e ; , muon ; and tau ; and their corresponding neutrinos e , and . In addition, all these particles have their antiparticles, with the possible exception of neutrinos. These spin-1 2 fermions are grouped into three families, each consisting of a quark pair and a lepton pair: u, d, e, e ; , c, s ; and t, b ; . The forces described by the SM are responsible for the electromagnetic felt by quarks and charged leptons e, and ; , strong felt by quarks ; and weak felt by all left-handed fermions ; interactions. Today the SM is a well established theory, precisely tested and widely applicable in particle physics processes. Nevertheless, there are strong reasons to believe that there is physics beyond it, i.e. that the SM is only a low-energy effective theory which may have to be modified at higher energies, possibly already at the TeV scale. From the theoretical point of view, the SM has a disturbingly large number of parameters, e.g. all particle masses, whose values the theory leaves undetermined. A complete theory is expected not just to describe but to explain the values of particle masses, as well as to answer the other open questions, such as why the number of particle families is three. Also, as mentioned, the SM does 7. Resident Choice A resident and or representative s ; has the right to be informed about the resident's condition; treatment options, relative risks and benefits of treatment, required monitoring, expected outcomes of the treatment; and has the right to refuse care and treatment. If a resident refuses treatment, the facility staff and physician should inform the resident about the risks related to the refusal, and discuss appropriate alternatives such as offering the medication at another time or in another dosage form, or offer an alternative medication or non-pharmacological approach, if available. Advance Directives A resident may have written or verbal directions related to treatment choices or a decision has been made by the resident's surrogate or representative ; in accordance with state law. An advance directive is a means for the resident to communicate his or her wishes, which may include withdrawing or withholding medications. Whether or not a resident has an advanced directive, the facility is responsible for giving treatment, support, and other care that is consistent with the resident's condition and applicable care instructions. NOTE: Choosing not to be resuscitated reflected in a "Do Not Resuscitate" DNR ; order ; indicates that the resident should not be resuscitated if respirations and or cardiac function cease. A DNR order by itself does not indicate that the resident has declined other appropriate treatment and services. Sediste Alidoste Nouhjah, Faculty of Public health. Scholl of Health, Ahwaz Medical Sciences University, Iran. Advertised before acceptance under section 20 ; 1 proviso Readvertisement of the trademark, since earlier advertisement published in Journal No.1328 S 5 ; is Cancelled 1259091 - 05 01 2004 PATEL VIPULKUMAR JASVANTBHAI, PATEL ROHITKUMAR RAMESHBHAI, PATEL SOMABHAI CHAGANDAS, PATEL PUSHPABEN RAMESHBHAI, PATEL JAYSHRIBEN VIPULBHAI, PATEL KANTABEN JASHVANTBHAI, trading as GREEN CROSS REMEDIES, HIGHWAY, AT: BILIYA 384154, DIST, PATAN, GUJARAT. MANUFACTURERS & MERCHANT User claimed since 31 07 2003 AHMEDABAD ; PHARMACEUTICAL PREPARATION & FORMULATION FROM VARIOUS EXCIPENTS INCLUDING CLASS 5. REGISTRATION OF THIS TRADE MARK SHALL GIVE NO RIGHT TO THE EXCLUSIVE USE OF WORD "REMEDIES.

Rundle, Marie Leader of the National Ocean Sciences Bowl program NOSB ; both nationally and in our local and statewide communities Provides materials and information for scientists to use when working with K-12 audiences, and provides outreach volunteer opportunities for scientists Rye, Barry Topical Editor, Applied Optics Optical Society of America ; Reviewed journal papers Applied Optics, Journal of Atmospheric and Oceanic Technology ; and SBIR proposals Dept. of Energy ; Sardeshmukh, Prashant CIRES Co-coordinator in the production of CDC's Science Program Review document for the 4-year CDC Review Compiled Book of Abstracts of CDC publications for distribution to the CDC reviewers Wrote Chapter 2 "Modeling Research on Seasonal to Interannual Variability" ; and most of Chapter 3 "Understanding and Predicting Subseasonal Variations" ; in the CDC Science Program Review document with input from other CDC scientists Reviewed journal articles for the Journal of Climate, Monthly Weather Review, Climate Dynamics, Science, Tellus and the International Journal of Climatology Reviewed proposals submitted to NSF and NOAA OGP Saunders, James Science Fair judge at Foothill Elementary School, Boulder, Co Manuscript reviewing: Water Research proposal reviewing: EPA STAR program, National Sea Grant program Scambos, Ted Presentations at local Elementary School: "The Chemical Elements" Presentations for numerous radio, TV, and newspaper interviews on Antarctica and Global Change Schafer, Robert Field day guide for high school students from Steamboat Springs, Co, showing them the radars meteorological instruments at Platteville Atmospheric Observatory, Platteville, Co CIRES Computing Advisory Committee member Review of 2 journal articles for Journal of Atmospheric and Oceanic Technology Review of 1 journal article for Geophysical Research Letters Scharfen, Gregory Serves on the SCAR COMNAP Joint Committee on Antarctic Data Management Serves on the MODIS Snow and Ice Products Ad Hoc Advisory Group Schubert, Rob Member, Architectural Review Committee - Waneka Pointe Homeowners Association CIRES Members Council representative Adopt-A-Highway Program Coordinator representing CIRES Schweitzer, Roland Host OAR "Web Tea" bimonthly technical discussion of Web technology Scott, Donna CIRES' Members, Council representative.

Abilify and depression dosage

Abilfy, abilicy, abikify, abilif7, abilifyy, bailify, abilkfy, abliify, abil8fy, abiliffy, abilofy, ahilify, abiliy, abulify, abolify, abillify, abiilify, ab8lify, abbilify, ailify, abiligy, abiliify, abilidy, abiliyf, abilifh, abiify, aiblify, abillfy, qbilify.

Abilify generic aripiprazole

Abilify 20mg side effects, abilify medicine bipolar, abilify otsuka bristol, abilify breastfeeding hale and abilify side effects medication. Abilify and depression dosage, abilify generic aripiprazole, taking abilify and seroquel together and abilify classification aripiprazole or abilify generic name.

Taking abilify and seroquel together

Brachial vein arm, minoxidil 2 for men, cyclophosphamide cancer, end stage renal disease wiki and casein list. Shopaholic dictionary, thimerosal msds, meloxicam structure and augmentin liquid or t4 endonuclease v enzyme.






 
   
 


 
© 2005-2008 Mar.freeoda.com, Inc. All rights reserved.